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Background: After stroke, pneumonia is a relevant medical complication that can be precipitated by aspiration of
saliva, liquids, or solid food. Swallowing difficulty and aspiration occur in a significant proportion of stroke survivors.
Cough, an important mechanism protecting the lungs from inhaled materials, can be impaired in stroke survivors,
and the likely cause for this impairment is central weakness of the respiratory musculature. Thus, respiratory muscle
training in acute stroke may be useful in the recovery of respiratory muscle and cough function, and may thereby
reduce the risk of pneumonia. The present study is a pilot study, aimed at investigating the validity and feasibility of
this approach by exploring effect size, safety, and patient acceptability of the intervention.
Methods/design: Adults with moderate to severe stroke impairment (National Institutes of Health Stroke Scale
(NIHSS) score 5 to 25 at the time of admission) are recruited within 2 weeks of stroke onset. Participants must be
able to perform voluntary respiratory maneuvers. Excluded are patients with increased intracranial pressure,
uncontrolled hypertension, neuromuscular conditions other than stroke, medical history of asthma or chronic
obstructive pulmonary disease, and recent cardiac events. Participants are randomized to receive inspiratory,
expiratory, or sham respiratory training over a 4-week period, by using commercially available threshold resistance
devices. Participants and caregivers, but not study investigators, are blind to treatment allocation. All participants
receive medical care and stroke rehabilitation according to the usual standard of care. The following assessments are
conducted at baseline, 4 weeks, and 12 weeks: Voluntary and reflex cough flow measurements, forced spirometry,
respiratory muscle strength tests, incidence of pneumonia, assessments of safety parameters, and self-reported
activity of daily living. The primary outcome is peak expiratory cough flow of voluntary cough, a parameter
indicating the effectiveness of cough. Secondary outcomes are incidence of pneumonia, peak expiratory cough
flow of reflex cough, and maximum inspiratory and expiratory mouth pressures.
Discussion: Various novel pharmacologic and nonpharmacologic approaches for preventing stroke-associated
pneumonia are currently being researched. This study investigates a novel strategy based on an exercise intervention
for cough rehabilitation.
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Stroke-associated pneumonia
Pneumonia is a well-reported medical complication after
stroke, in particular within the first weeks and months
after the event. A recent review [1] identified 54 pub-
lished studies reporting the incidence of pneumonia
after stroke. These publications span from 1998 to 2012
and present data from intensive care, acute, and rehabili-
tation settings. The reported incidence of pneumonia is
highest in intensive care patients (median, 27%; range,
4.1% to 56.6%), although ventilator-associated pneumo-
nia may be a confounding factor in this setting. For
acute stroke units, general medical wards, and rehabilita-
tion units, the reported incidence of pneumonia ranges
from 3.9% to 45%, with a median incidence rate of 7.4%.
Studies differ in the criteria for the diagnosis of pneumo-
nia, characteristics of study samples, and time periods of
observation, and it may not be appropriate to compare
studies directly. The most current and valid data avail-
able for the United Kingdom (UK) is from the national
stroke audit for England, Wales, and Northern Ireland,
which showed incidence rates of 16% in 2008 [2] and
13% in 2010 [3].
Pneumonia after stroke is associated with worse patient
outcomes. Patients in whom pneumonia develops have an
estimated twofold to sixfold increase in risk of death [4-15],
are approximately 3 to 6 times more likely to have poor
scores on various rehabilitation measures [6,7,11,12,16],
stay in the acute hospital on average for 3 times longer than
those without pneumonia, and also require higher levels of
care after hospital discharge [4,7,9,12,14,17,18].
Swallowing difficulty (dysphagia) is one of the most
frequently identified predictors of poststroke pneumonia
[1,7,13,19-23]. Dysphagia is common in stroke, with an
average incidence rate of 40% [24], although reported
figures vary (14% to 94%) because of differences in
sample selection and method and timing of swallow as-
sessments [23,25-28]. Dysphagia is associated with an
approximately twofold to threefold increase in risk of
developing poststroke pneumonia [7,13,19-23]. This risk
increases to fivefold to 11-fold with worsening severity
of swallowing difficulty, the presence of aspiration (ma-
terial entering the trachea past the vocal cords), and
worsening severity of aspiration [23,29-31]. Several stud-
ies highlight the risk posed by silent aspiration (aspir-
ation that occurs without triggering a protective cough)
and the protection cough provides from aspiration pneu-
monia [32-34]. Some studies also demonstrate the associ-
ation between weak or absent cough and higher incidence
of aspiration in stroke survivors [35,36].
Strategies for preventing stroke-associated pneumonia
To date, the single most successful strategy to prevent
poststroke pneumonia has been the early detection ofswallowing difficulty through routine swallow screening,
followed by implementation of dysphagia-management
strategies [1,9,21,37]. Various approaches to further re-
duce poststroke pneumonia rates are currently being
researched. Pharmacologic approaches include the pre-
ventive administration of antibiotics [1,38], the use of
ACE inhibitors to improve reflex cough sensitivity [39],
and approaches targeting stroke-induced immunode-
pression [1]. Nonpharmacologic strategies include ele-
vated body positioning to prevent aspiration [39] and
reduction of oropharyngeal pathogens through intensive
oral hygiene [1,39]. The present study investigates a
novel nonpharmacologic approach, by using respiratory
muscle training (RMT) to improve cough effectiveness
and airway protection in acute stroke patients.Cough impairment in acute stroke
Cough is an important mechanism to protect from aspir-
ation. It requires the coordinated activation of respiratory
muscles (inspiratory and expiratory) and intrinsic laryn-
geal muscles. In a cough maneuver, inspiratory muscle ac-
tion first causes air to be drawn into the lungs. Expiratory
muscle contraction then creates a buildup of intrathoracic
pressure against a closed glottis. Finally, a blast of air is re-
leased by rapid glottis opening, producing the characteris-
tic cough sound and moving particles from the lungs
toward and into the pharynx [40].
Stroke can adversely affect cough function. Peak ex-
piratory cough flow (PECF), a measure of cough effect-
iveness, was found to be reduced by approximately one
third in acute and chronic stroke patients when com-
pared with healthy elderly subjects and normative values
[41,42]. In detailed physiological studies of cough and
respiratory muscle function, acute stroke patients were
compared with matched healthy control subjects [43,44].
It was found that parameters of respiratory muscle
strength (maximum inspiratory and expiratory mouth
pressures, sniff pressure) and cough (PECF, gastric pres-
sure during cough) in stroke subjects were reduced by
one third to one half. This was demonstrated in volun-
tary and reflex cough. No difference between stroke and
control subjects was found in the function of the intrinsic
laryngeal muscles (glottis-closure phase during cough); or
in respiratory muscle function when muscles were stimu-
lated peripherally [43,44].
These findings demonstrate that a significant impair-
ment of cough and respiratory muscle function occurs
in acute stroke; that the impairment of cough function is
likely related to respiratory muscle weakness, as opposed
to dysfunction at the level of the glottis; and that the re-
spiratory muscle weakness is related to the central com-
ponent of the motor pathway (that is, the stroke lesion).
Thus, an intervention targeting stroke-induced central
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ness and reduce the risk of stroke-associated pneumonia.
Respiratory muscle training in stroke
Respiratory muscle training (RMT) aims to improve re-
spiratory performance by loading the respiratory system
beyond its usual level of functioning, thereby creating
a training effect [45-48]. Much research on RMT has
been conducted in healthy subjects, in athletes, and in
clinical populations with primary respiratory problems.
A small number of studies have investigated RMT in
groups with neurologic conditions [49]. Two rando-
mized controlled trials of inspiratory muscle training by
using the threshold loading technique were conducted
in chronic and subacute stroke patients [49-52]. Both
trials demonstrated statistically significant improve-
ments in inspiratory muscle strength and other physio-
logical parameters for the RMT groups. Although the
observed effect sizes were modest in absolute terms,
these studies provide proof of principle that physio-
logical improvement in stroke survivors is achievable
through RMT.
Aims and objectives
The present study investigates whether RMT is a worth-
while treatment approach to pursue for the reduction of
pneumonia rates in acute stroke patients. The aim is
to provide estimates on its magnitude of effect, accep-
tability, safety, and feasibility, and to inform about the
value and design of a large clinical trial. The study objec-
tives are (a) to determine the magnitude of effect of the
intervention on cough generation, respiratory muscle
strength, and incidence of pneumonia; (b) to explore the
training duration, frequency, and intensity required to
achieve improvement in cough flow and inspiratory and
expiratory muscle strength; (c) to evaluate patient par-
ticipation, acceptability of study procedures to partici-
pants, and concordance with training protocol; (d) to
describe safety parameters and potential adverse effects
of RMT in this patient group; (e) to describe characte-
ristics of those patients most likely to gain from the
intervention; and (f ) to determine the relevance and
feasibility of delivering RMT to acute stroke patients in




The study is a pilot study, designed as a single-blind
randomized controlled trial with three study groups.
Participants are randomized to receive inspiratory
muscle training, expiratory muscle training, or sham
RMT. After the baseline assessment, participants
undergo a 4-week intervention period. Weekly investigatorvisits are conducted during the intervention period. The
primary study end point is at the end of the intervention
period (day 29). A final reassessment is conducted at
12 weeks after baseline. One investigator conducts all
study procedures, including screening for eligibility,
gaining consent, conducting study assessments, and
introducing and assisting with the intervention. A sum-
mary of the study timeline and all data collected is given
in Additional file 1. The participant flow through the
study is described in Figure 1.
Study setting
Acute stroke patients are screened for eligibility at one
Hyperacute Stroke Unit (HASU) at one tertiary center
in London, UK. Participants receive medical care and
stroke rehabilitation according to the current standard
of care. During the study period, participants may be
discharged home or transferred to specialized stroke-
rehabilitation units within the geographic area.
Participants
The population of interest for this study comprises all
patients admitted to hospital with an acute stroke,
except for those with very mild stroke symptoms or
without weakness. The inclusion and exclusion criteria
reflect the nature of the study procedures, which require
the participant to carry out volitional respiratory ma-
neuvers with adequate technique; and the potential
vulnerability of this acute patient group to extreme
changes in intrathoracic pressures, which may be caused
by respiratory maneuvers.
Inclusion criteria for the study are as follows:
– Age 18+ years
– Confirmed medical diagnosis of acute stroke
(ischemic or hemorrhagic)
– Moderate to severe stroke impairment, defined as
National Institutes of Health Stroke Scale (NIHSS)
[53] score 5 to 25 and stroke-related weakness at the
time of admission
– Within 2 weeks of stroke onset
– Ability to follow instructions and engage in study
procedures
– Ability to give informed consent
Exclusion criteria are as follows:
– Signs of increased intracranial pressure on
computed tomography (CT) scan
– Poorly controlled hypertension, defined as
blood pressure higher than 180/100 at three
or more occasions over the preceding 24 hours
– Myocardial infarction, angina, or acute heart
failure in the preceding 3 months
All patients admitted to the hyper-acute 
stroke unit are screened for eligibility
Eligible patients are approached and 
invited to take part in the study
Written informed consent is gained from 
patients who agree to take part
Randomisation
Baseline assessment (day 0)
Intervention 





Final assessment (week 12)
Baseline assessment (day 0)
Intervention 





Final assessment (week 12)
Baseline assessment (day 0)
Intervention 














Figure 1 Flowchart of study design.
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orthopedic conditions adversely affecting the
respiratory pump, including asthma and chronic
obstructive pulmonary disease (COPD)
Informed consent and ethical approval
Eligible patients are approached and invited to take part
in the study. The study purpose and procedures are ex-
plained, taking into account any communication diffi-
culties caused by the stroke. A study information sheet
is provided. Patients are given at least 24 hours to con-
sider the study. Only patients who have the ability to
give informed consent are eligible. Patients who are
willing to take part sign a written consent form. The study
was granted ethical approval from the UK National
Research Ethics Service (NRES) (Wandsworth Research
Ethics Committee, study reference 10/H0803/32).
Randomization, blinding, and treatment allocation
Sequentially numbered sealed envelopes containing the
treatment allocation were prepared by a researcher unre-
lated to the study team. The randomization sequence
was computer-generated. Block randomization (blocks
of 12, containing four participants per study arm) was
used to ensure even participant spread across the trial
groups.
For each participant, the investigator opens the respective
envelope after informed consent has been gained and im-
mediately before conducting the study baseline session.
Thereafter, the investigator is aware of the participant’sgroup allocation. Participants, caregivers, and healthcare
professionals are unaware of group allocation throughout
the study period.
Intervention
The intervention consists of a respiratory muscle-
strengthening exercise, by using the threshold RMT
method [54]. A training stimulus is given by asking
participants to breathe repeatedly in (inspiratory muscle
training) or out (expiratory muscle training) through
a commercially available hand-held resistance device
(Threshold IMT, Threshold PEP; Respironics, Parsippany,
NJ, USA). Participants are asked to train daily over a
4-week period. Every day, participants perform five sets of
10 breaths with the device, with resting periods of 1 mi-
nute between sets. The training resistance is set at 50% of
the individual’s maximum mouth pressure (maximum
inspiratory mouth pressure for the inspiratory training
group, maximum expiratory mouth pressure for the ex-
piratory training group). Maximum mouth pressures are
reassessed weekly, and the training resistance readjusted
accordingly. Participants in the sham training group are
also given a training device, with the resistance set to an
ineffectual 10% of maximum mouth pressure.
Participants are instructed in the correct training tech-
nique by the investigator during the baseline session,
and training technique is reviewed weekly. To document
concordance with training, participants keep a training
diary, noting the frequency of training and any problems
encountered.
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Additional file 1 gives an overview of the data collected
at the respective time points. Peak expiratory cough flow
(PECF) of voluntary cough at the end of the intervention
period (day 29) is taken as the primary study outcome.
This is in keeping with the clinical scenario of aspiration
and resulting pneumonia. PECF is the parameter that
indicates the speed of the air expelled from the lungs
during the expulsion phase of cough. Voluntary cough
PECF therefore reflects a person’s capacity to move
aspirated particles from the lower airway back above the
vocal cords and into the pharynx through a voluntary
cough maneuver [55]. Secondary study outcomes are
incidence of pneumonia, maximum mouth pressures, and
peak expiratory cough flow of reflex cough at day 29.
Participants’ age, height, and weight at the time of hos-
pital admission are recorded from clinical records.
Swallow safety is determined from the clinical swallow
assessment, conducted routinely for patients admitted
with acute stroke. This entails a swallow screen adminis-
tered by a trained nurse. The swallow screen is con-
ducted according to a clinical algorithm and includes
observation of alertness, oro-motor function, and swal-
lowing function. If concerns are raised, the medical team
and the speech and language therapist are alerted. A
clinical swallow examination by a speech and language
therapist is performed, and swallow-management strat-
egies are implemented. In specific cases, an instrumental
assessment of swallowing function is performed.
For the purpose of the present study, the swallow is
deemed unsafe if any precautionary instructions are issued
for the participant, such as nil by mouth, recommenda-
tions of modified food textures, or specific swallowing
techniques. The swallow is deemed safe, if the participant
is allowed to swallow normal fluids and a normal diet
without any explicit precautionary instructions.
The presence of pneumonia is determined from clinical
records, from communication with the medical team,
and from the participant directly.
The Nottingham Extended ADL Scale [56], a self-
reported questionnaire, is used to assess participants’ func-
tional independence in activities of daily living (ADLs).
All respiratory testing is conducted with the participant
seated comfortably, or positioned sitting up in the hospital
bed. Forced spirometry (forced expiratory volume at 1 se-
cond (FEV1), forced vital capacity (FVC), and peak expira-
tory flow (PEF)), is conducted according to international
clinical standards [57], by using a portable spirometer
(SpiroUSB; CareFusion, San Diego, CA, USA) and a
bacterial filter (Spiroguard Standard; Air Safety Medical,
Morecambe, England). A flanged mouthpiece (Rubber
Flanged Mouthpiece MTH6400; CareFusion) is used to
create an optimal mouth seal in the presence of orofacial
weakness. Forced spirometry provides an assessment ofparticipants’ lung function, and in particular of airway ob-
struction and restriction.
Respiratory muscle strength is assessed through meas-
urement of maximum expiratory mouth pressure (MEP)
and maximum inspiratory mouth pressure (MIP), accord-
ing to international clinical standards [58]. A portable
clinical device (MicroRPM; CareFusion) is used with a
bacterial filter (Mouth Pressure Bacterial Filters FIL6050;
CareFusion) and a flanged mouth piece (Rubber Flanged
Mouthpiece MTH6400; CareFusion).
Cough flow measurements are conducted with a cali-
brated pneumotachograph system [59]. An on-site and
an off-site measurement system are used. The on-site
system is used for measurements at the primary study
site. The off-site system is used for measurements out-
side the primary study site, for example at the neighbor-
ing stroke-rehabilitation unit or at participants’ homes.
The on-site system consists of a Fleisch-type pneumo-
tachograph (ID 4 cm, length 6 cm; PK Morgan Ltd,
Rainham, England) connected to a face mask (Adult
Face Mask, 8940 Series; Hans Rudolph Inc., Kansas City,
MO, USA); a differential pressure transducer (MP45-14-
871, range ± 2 cmH2O; Validyne Engineering, Northridge,
CA, USA); a demodulator (CD15; Validyne Engineering);
an analog-to-digital converter (PowerLab/16SP; ADInstru-
ments Ltd, Oxford, England); and a laptop running
LabChart data-acquisition software (LabChart Pro, ver-
sion 7.2.2; ADInstruments Ltd).
For the off-site system, a different analog-to-digital con-
verter (NI BNC-2110; National Instruments, Newbury,
England) and laptop with data-acquisition software
(LabView, version 5.1, National Instruments) are used.
The on-site and off-site systems have the same per-
formance characteristics: linear response from zero to
700 L/min in both directions of flow; frequency re-
sponse of >20 Hz; and analog-to-digital sampling of
2 kHz. The systems are calibrated before each testing
session by two-point calibration with a rotameter
(InFlux OF1”S, 60 to 600 L/min flow; Techniquip Ltd,
Taunton, England) at a reference flow of 500 L/min.
Voluntary and reflex coughs are assessed. For volun-
tary coughs, participants make repeated maximal cough
efforts into a tight-fitting face mask, until five coughs of
similar PECF are recorded. To elicit reflex coughs, es-
calating concentrations of capsaicin (0.49 to 1,000 μM)
are nebulized (UltraNeb U3000; DeVilbiss Healthcare
Ltd, Tipton, England) and introduced into the face
mask for 1 minute at a time, until the threshold is
reached at which five bouts of reflex coughing are trig-
gered. From the recorded cough-flow traces, the follow-
ing parameters are derived for the five voluntary and
five reflex coughs with the highest peak expiratory flow
rates: peak expiratory cough flow (PECF), peak inspira-
tory cough flow (PICF), volume expired (VE), volume
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volume acceleration.
To monitor the safety of the intervention, blood
pressure, heart rate, and blood oxygen saturation are
measured before and after participants carry out RMT.
Measurements are made by using a digital blood pres-
sure monitor (UA-767 Plus; A&D Instruments Ltd,
Abingdon, Oxon, UK) and a finger pulse oximeter (Onyx
9500; Nonin Medical Inc, Plymouth, MN, USA). In
addition, the investigator notes any subjective discomfort
reported during training. Adverse events are noted and
reviewed throughout the duration of the study.
Sample size
The initial sample-size calculation was based on obser-
vations from a cross-sectional study of acute stroke pa-
tients [44] and a one-way analysis of variance (ANOVA)
model of statistical analysis [60,61]. For group sizes of
less than 50, ANOVA assumes that data are normally
distributed and that variances are equal. For the purpose
of this sample-size calculation, these assumptions were
made. With an estimated group standard deviation (SD)
of 50 L/min for the main outcome measure (voluntary
cough PECF at the primary end point), a sample size of
16 subjects per group gives the study 80% power to
detect a 50 L/min difference between groups at the 5%
significance level. Assuming an attrition rate of 20%, 20
subjects per study group are required, giving a total
sample size of 60.
The sample-size calculation was reviewed after the
first 40 participants completed their participation in the
study. At this point, participant attrition was higher than
anticipated (32%), and primary outcome data showed
greater variability than initially assumed, with group SD
ranging from approximately 100 to 250. Table 1 shows
estimates of the required number of participants per
group to give the study 80% power at the 5% significance
level, according to different treatment-effect sizes and
different group standard deviations. Taking into account
these observed data, the decision was made to increase
the study sample to 20 participants per group. This




Expected SD within group (L/min)
50 100 150 200 250 300
50 15 58 125 250 400 600
100 5 15 35 60 95 125
150 <5 8 15 26 42 58
200 <5 5 10 16 24 34
Estimates of required number of participants per study group to give 80% power
at the 5% significance level, according to different expected treatment-effect
sizes and different expected group standard deviations (SDs) of the primary
outcome (peak expiratory cough flow (PECF) of voluntary cough).should the data show large within-group variability.
Also, it was considered a realistic recruitment target,
given the observed rate of recruitment and the resources
available. Taking into account a dropout rate of approxi-
mately 30%, the revised target sample is 90 subjects,
whereby recruitment will be concluded early once 20
participants per group complete the primary study end
point.Statistical analysis
Descriptive statistics will be used to present group char-
acteristics at baseline; to compare study completers with
participants who discontinued the study; and to compare
participants with good training completion with those
with poor training concordance. Training-safety data
will be summarized descriptively and compared against
pre-set safety parameters (standard safe ranges of vital
parameters as used in clinical practice).
Inferential statistics will be used to evaluate the effect of
treatment on the primary and secondary outcome param-
eters. The hypotheses under investigation are as follows:
RMT (inspiratory or expiratory) is effective for improving
voluntary cough effectiveness (voluntary cough PECF);
RMT (inspiratory or expiratory) is effective for improving
reflex cough effectiveness (reflex cough PECF); expiratory
muscle training is effective for improving expiratory
muscle strength (MEP); inspiratory muscle training is
effective for improving inspiratory muscle strength (MIP);
RMT (inspiratory or expiratory) is effective for reducing
the incidence of pneumonia.
The sample-size calculation followed an ANOVA
model of inferential statistical analysis. However, it is an-
ticipated that the study sample will show considerable
heterogeneity, in which case, an analysis of covariance
(ANCOVA) model is more powerful in detecting a
difference in study arms [62]. ANCOVA will be used to
compare group means of voluntary and reflex cough
PECF, MEP, and MIP at the primary end point (day 29).
The following covariates will be adjusted for: gender,
age, smoking, stroke severity (NIHSS score), training
intensity, and a predictor variable for “missingness”, which
will be determined through logistic regression. Fisher
Exact test will be used to compare the incidence of pneu-
monia from baseline through week 4 between the three
study groups. Adjustments for multiple testing will be
made by using the Benjamini-Hochberg method [63].
Four approaches to dealing with missing values will
be compared in a sensitivity analysis: intention-to-treat
analysis, substituting missing values through predictive
model-based imputation [64]; intention-to-treat analysis,
substituting missing values through propensity score im-
putation [65]; intention-to-treat analysis, substituting mis-
sing values with baseline data; and complete case analysis,
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mary end point.
Further exploratory analyses may be conducted as
thought appropriate, and any relevant findings will be
reported accordingly.
The data-analysis plan has undergone some revision as
the picture of the actual data observed became clearer
with ongoing data collection, and it includes sensitivity
and exploratory analyses. This flexible approach to data
analysis is justified in this study, which is understood as
a pilot project. Discovering what type of data can be ex-
pected in this population and comparing alternative stat-
istical analysis approaches for these data falls within the
aim of the project to inform the design of a larger clin-
ical trial. However, the primary and secondary end
points for the study have been clearly defined and have
remained unchanged from the outset, and the results
will be reported accordingly and in a transparent
manner, regardless of “positive” or “negative” results. Al-
though participant-level data will not be made publicly
available, the data will be archived at the study center
for 10 years according to regulatory requirements, where
it will be available for scrutiny. Details of the statistical-
analysis code will be included in the full study report.
Dissemination
The research will be summarized in a technical report to
the funding agency, the UK National Institute for Health
Research (NIHR). This report will be in the public do-
main. The findings of the research will be disseminated
locally, regionally, and nationally to professional and user
groups through established research and service networks
(for example, the South London Stroke Research Group,
the UK Stroke Forum and the UK Stroke Research
Network). A summary of findings written in lay language
will be posted to study participants who wish to be in-
formed about the study outcome. We will seek publication
in peer-reviewed journals and presentations at inter-
national scientific meetings to reach the wider healthcare
community. To ensure that the validity and scientific
value of the study can be adequately evaluated by con-
sumers of research, study reporting will follow the CON-
SORT [66,67] and CONSORT for nonpharmacologic
interventions [68] guidelines. All dissemination outputs
from the study require approval from the funding agency
(UK NIHR) before publication.
Discussion
Strengths
To our knowledge, the present study is the first to ex-
plore respiratory muscle strengthening as a means to
improving cough effectiveness and protecting from
pneumonia in acute stroke. Although little research has
been conducted in this area to date, several studies ofgood methodologic quality provide a physiological ra-
tionale and demonstrate the potential for physiological
improvement through RMT in stroke.
The current study applies a method of cough flow meas-
urement that is detailed and physiologically accurate. This
method compares favorably with the use of portable peak
flow meters, which have been used in other clinical studies
in spite of uncertainty over their accuracy in measuring
cough flow.
Weaknesses
The methods for identifying the presence of swallowing
difficulty and pneumonia in the current study may be
regarded as a limitation. To minimize participant burden
created by additional medical procedures, it was decided
to take a pragmatic approach and observe clinical and
self-reported information on swallowing function and
pneumonia. A more-detailed instrumental assessment of
swallowing, such as video-fluoroscopic examination of
swallow, could be used to determine the degree of dys-
phagia and aspiration. Objective diagnostic criteria for
pneumonia, including assessments of chest radiographs
and blood results [69,70], could be used to support the
detection of pneumonia.
A further limitation to the study is the lack of investi-
gator blinding. The investigator is masked to treatment-
allocation sequence, but is aware of group allocation
from the point of randomization.
Although the clinical purpose of this research is to re-
duce the risk of pneumonia after stroke, the study uses
voluntary cough flow as a surrogate primary outcome.
This surrogate outcome was selected to minimize the re-
quired sample size. Designing the study according to the
primary outcome, pneumonia, would require a consider-
ably larger sample. For example, it could be assumed
that both intervention groups would show a reduction
in pneumonia rates from 15% to 7.5% compared with
the control group. To give 80% power at the 5% signifi-
cance level, this would require approximately 180 partic-
ipants per group (using the χ2 test and not accounting
for attrition).
The choice of voluntary cough flow as a surrogate
primary outcome in this study was based on the physio-
logical rationale to the research. Also, good evidence
shows that reduced voluntary cough flow in stroke
patients is associated with higher risk of aspiration, and
therefore aspiration pneumonia [35,36]. To our know-
ledge, the direct relation between voluntary cough flow
and pneumonia has not been investigated in stroke pop-
ulations. The importance of cough flow may be inferred
from populations with neuromuscular conditions, where
reduced levels of voluntary cough flow indicate the
need for assisted airway clearance [71]. The adequacy of
voluntary cough flow as a surrogate measure for
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a proportion of study participants will develop pneumo-
nia, and the association between voluntary cough flow
and pneumonia will be assessed by using descriptive sta-
tistics or logistic regression analysis, as appropriate.
As described, the initial sample-size calculation was
revised because of a higher-than-anticipated attrition
rate. It is important to maximize participant retention in
trials, to avoid conclusions that are biased through miss-
ing data [72]. It is anticipated that the present pilot
study will indicate strategies to minimize participant
attrition and missing data. So far, provision of transpor-
tation for participants free of charge and the option to
bring testing equipment to the participant’s location have
greatly improved participant retention. Further strategies
will be explored by reviewing reasons for discontinuing
the study and considering alternative methods of data
collection, in an effort to prevent missing data.
In conclusion, in trialing RMT in acute stroke, the
present study investigates a novel approach for preventing
poststroke pneumonia. Poststroke pneumonia presents a
multifaceted clinical problem, and different strategies for
reducing incidence rates are currently being researched.
The current study will provide valuable information on
the potential validity and feasibility of this particular
approach.
Trial status
Recruitment to the study started in March 2011 and is
expected to be complete by April 2014.
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